For how we live.
The final VISIONARY analysis shows Voyxact flattened the two-year eGFR slope to 0.3 versus a 4.2 mL/min decline on placebo, and cut the composite kidney endpoint to 0.4% of patients from 11.2%.
RAINIER's interim analysis found the dual APRIL/BAFF inhibitor cut urinary protein by 52% at nine months versus 4% on placebo, but the kidney-function answer is still years away.
ORIGIN 3's final analysis found the APRIL/BAFF inhibitor stabilised kidney function and left 5.1% of patients progressing versus 17.8% on placebo, with none reaching dialysis, transplant or death on the drug.
The complement inhibitor lowered urinary protein by 43% versus placebo at week 34 in the interim I CAN trial, extending a drug already used in rarer disorders to the kidney's most common immune disease.
Final ALIGN results show the endothelin blocker preserved kidney function over 2.5 years in a rare kidney disease, yet the difference at week 136 just missed statistical significance (p=0.057).
Voyxact cut urinary protein by about half at nine months in the VISIONARY trial. Whether that slows kidney decline is the question the accelerated approval leaves open until 2027.